Newsroom

SAN CARLOS, CA – January 7, 2026 – Alessa Therapeutics (“Alessa”), a clinical stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage prostate cancers, today announced that the Company will be presenting at the 44th Annual J.P. Morgan Healthcare Conference, being held at The Westin St. Francis Hotel in San […]

SAN CARLOS, CA (January 9, 2025) – Alessa Therapeutics, Inc., a privately held drug development company developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease, announced the enrollment of the first patient in the company’s Enolen® clinical study at the National Cancer Institute (NCI), part of the National Institutes of […]

SAN CARLOS, CA (December 16, 2024) – Alessa Therapeutics, a clinical-stage drug development company pioneering an innovative and proprietary localized drug delivery technology for the early treatment of prostate cancer and other diseases, announced today the appointment of Cam Gallagher as President and Chief Executive Officer, effective immediately. Mr. Gallagher, a seasoned leader and serial entrepreneur […]

SAN CARLOS, CA (December 12, 2024) – Alessa Therapeutics, Inc., a clinical-stage drug development company pioneering an innovative and proprietary localized drug delivery technology for the early interception of cancer and other diseases, announced the closing of a $15M seed financing led by Mission BioCapital joined by Johnson & Johnson (through its corporate venture capital organization, […]

San Carlos, Calif., April 22,2024 – Alessa Therapeutics Inc. today announced that they will be presenting a podium poster at the 2024 annual American Association of Urology (AUA) annual meeting in San Antonio, TX. Poster Title: A Phase 1 Safety, PK and Preliminary Efficacy Study of Localized Therapy using Biolen (Bicalutamide) Implants for Early-Stage Prostate CancerSession […]

San Carlos, Calif., March 26,2024 – Alessa Therapeutics Inc. today announced that they will be presenting a poster at the 2024 annual European Association of Urology (EAU) annual meeting in Paris, FR. Poster Title: A Phase 1 Safety, PK and Preliminary Efficacy Study of Localized Therapy using Biolen (Bicalutamide) Implants for Early-Stage Prostate CancerSession Date and […]

SAN CARLOS, CALIFORNIA, US, February 23, 2022 /EINPresswire.com/   Alessa Therapeutics, Inc., a clinical-stage drug development company developing an innovative and proprietary localized drug delivery technology to treat prostate disease, announced the enrollment of the first two men with prostate cancer in the company’s Biolen+RT clinical study. Biolen+RT (NCT 04943536) is a Phase 1 clinical […]

SAN CARLOS, CALIFORNIA, US, October 11, 2021 /EINPresswire.com/   Alessa Therapeutics, Inc., a clinical-stage drug development company developing implantable drug delivery systems focused on sustained delivery of drugs to solid organ tumors, announced that it has entered into a research collaboration agreement with an affiliate of Janssen Research & Development, LLC. This agreement was facilitated by Johnson […]

SAN CARLOS, CALIFORNIA, US, June 7, 2021 /EINPresswire.com/   Alessa Therapeutics, Inc., a clinical-stage drug development company developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease, announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) for Biolen®. Alessa, in collaboration with […]

SAN CARLOS, CALIFORNIA, US, March 17, 2020 /EINPresswire.com/   Alessa Therapeutics, Inc., a privately held drug development company developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease, announced the enrollment of the first patient in the company’s Biolen-PC clinical study in Australia. Biolen-PC (NCT 04284761) is a first-in-man study […]